Brief: aTyr Pharma Receives FDA Fast Track Designation For Efzofitimod For Treatment Of Systemic Sclerosis-Associated Interstitial Lung Disease
13/09/2022 15:07
Sept 13 (Reuters) - aTyr Pharma Inc LIFE.O :
* ATYR PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR
EFZOFITIMOD
FOR TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG
DISEASE (SSC-ILD)
Source text for Eikon: ID:nGNX88dB8v
Further company coverage: LIFE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan